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     INTRODUCTION 
  Primaquine is the only widely available hypnozoitocidal 
drug for   Plasmodium vivax   and   P. ovale   malaria .  Primaquine 
at the dose most usually recommended in the past for radical 
cure (15 mg base adult dose daily for 14 days) is also weakly 
effective against asexual stages of   Plasmodium vivax   malaria. 1  
The standard chloroquine and primaquine treatment regimen 
may therefore be considered as a combination treatment. The 
dose-response relationship for primaquine’s asexual stage 
activity is uncertain. Higher doses of primaquine may be more 
effective than standard doses but also increase the risk of 
adverse effects. Primaquine is associated with upper gastroin-
testinal discomfort, particularly if taken on an empty stomach, 
and causes oxidant hemolysis in subjects who have glucose-
6-phosphate dehydrogenase (G6PD) deficiency. In malaria 
prophylaxis, a 30 mg daily dose of primaquine has been shown 
to be well tolerated even when given continuously for as long 
as 20 weeks.  2,  3   For radical cure of vivax malaria in normal 
G6PD patients, adult doses of primaquine at 22.5 to 30 mg 
proved safe and effective in Thailand,  4,  5   and the higher dose 
(0.5 mg base/kg) has recently been recommended by the World 
Health Organization. In Thailand   Plasmodium vivax   has a 3 
week interval between primary infection and the first relapse, 
and approximately half the patients experience at least 1 
relapse.  5–  8  -   The schizontocidal activity of primaquine  1   becomes 
increasingly important in the face of increasing chloroquine 
resistance in   P. vivax  , although the 2 week course currently 
recommended for radical cure remains a significant impedi-
ment to good adherence and therefore optimal efficacy. The 
dose-response relationships for primaquine’s asexual stage 
and hypnozoitocidal activities have not been well character-
ized. To compare these 2 discrete activities and to assess effi-
cacy and tolerability, we evaluated 7-day courses of 30 mg and 
60 mg daily primaquine-only regimens for the treatment and 
radical cure of   Plasmodium vivax   malaria in Thailand. 
   PATIENTS AND  METHODS 
  Patients.     The study was conducted in adult male patients 
with acute symptomatic   Plasmodium vivax   malaria admitted 
to the Bangkok Hospital for Tropical Diseases, Thailand 
between 1996 and 1998. The study was approved by the ethics 
committee of the Faculty of Tropical Medicine, Mahidol 
University, Bangkok. All patients gave full informed consent. 
  All patients were screened and only those with normal 
G6PD testing were included. Other exclusion criteria were a 
history of drug hypersensitivity, having taken any antimalarial 
drugs within the previous 48 hours, or urine screening tests 
that were positive for sulfonamides (lignin test) or 4-amino-
quinolines (Wilson Edeson test). Patients who had patent 
mixed infections or were unable to stay in the hospital until 
clearance of both fever and parasitemia were excluded from 
the study. 
   Management.     After clinical assessment and confirmation of 
the diagnosis from thick and thin blood smears, baseline blood 
samples were taken for routine hematology and biochemistry. 
Treatments were allocated according to double-blinded 
randomization codes. The treatment allocation was kept in 
serially numbered sealed envelopes that were opened only 
after the patient had been enrolled in the study. Patients were 
randomized to receive 1 of the following 2 regimens: 
  1.     Primaquine  (Thai  Government  Pharmaceutical  Organi-
zation) 0.50 mg base/kg once daily (adult dose 30 mg base/
day) for 7 days   
    2.       Primaquine 1.0 mg base/kg once daily (adult dose 60 mg 
base/day) for 7 days.       
  Oral acetaminophen (0.5–1 g 4 hourly) was given for fever 
> 38°C. 
   Assessments  of  clinical  response.     Vital signs were recorded 
every 4 hours until resolution of fever and thereafter every 
6–12 hours. Fever clearance time was defined as the time 
for body temperature to fall below 37.5°C and remain 
below this value for > 48 hours. Early treatment failure was 
defined as persistence of fever and parasitemia for > 7 days or 
persistence of parasitemia in the absence of fever for > 14 days. 
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Reappearance of infection was assessed in patients who 
remained in Bangkok either in the hospital or at home (i.e., 
outside the malaria transmission area) for at least 28 days. 
Patients who failed to respond to the treatment, or those who 
had recurrent vivax infections were treated subsequently with 
the standard regimen of chloroquine (25 mg/kg base over 
3 days) and primaquine (0.25 mg base/kg/day for 14 days). 
Patients with delayed appearance of   P. falciparum   infection 
were treated with a 7-day course of quinine (10 mg salt/kg every 
8 hours) combined with tetracycline (250 mg every 6 hours) 
and censored from that time in the subsequent assessment. 
  Assessment of gastrointestinal symptoms (nausea, vomiting, 
diarrhea, and abdominal pain) and any other symptoms and 
signs was performed every day during and after primaquine 
treatment (day 0 to day 7, day 14, and day 28). Hematocrit 
was assessed daily during and after primaquine treatment. 
Laboratory investigations for full blood count and routine 
biochemical tests were performed before treatment (D0) and 
then on day 7, day 14, and day 28. 
   Parasitological  assessment.     Parasite counts of both sexual 
and asexual stages were measured every 2–12 hours in thin 
films and thick films until the parasitemia became detectable 
only in thick films, then every 12 hours until clearance, and 
thereafter daily for 28 days. Parasitemia was expressed as the 
number of parasites per microliter of blood (derived from the 
numbers of parasites per 1,000 red blood cells in the thin film 
stained with Giemsa or Field’s stain or calculated from the 
white count and the numbers of parasites per 200 white blood 
cells in the thick film). Gametocytes and asexual stages were 
counted separately. Gametocyte counts were calculated from 
the thick film only. Gametocyte carriage was expressed as 
the proportion of patients with patent gametocytemia either 
before treatment (i.e., on admission) or at any time after the 
start of treatment. The gametocyte clearance time was defined 
as the interval from the first detection of gametocytes in 
peripheral blood films either before or after treatment to the 
last detection of gametocytes. The variables describing parasite 
clearance were time taken until the asexual malaria parasite 
count fell by 50% (PC50), time taken to fall by 90% (PC90) of 
the pre-treatment admission value, and the time taken to fall 
below detectable levels in a peripheral blood smear (PCT); 
parasite reduction ratio (PRR) was the ratio of the parasite 
count before treatment to the counts at 24 hours and at 
48 hours. Recurrence of vivax malaria could have resulted from 
recrudescence or relapse but not re-infection because these 
patients remained out of the transmission area throughout the 
follow-up period. In an individual patient whose parasitemia 
cleared, recrudescence or relapse of   P. vivax   cannot be 
distinguished reliably.  9   Reappearance of parasitemia within 
28 days was therefore considered together as treatment failure. 
Reappearance rates were also compared with other studies 
conducted in the same hospital with similar patient populations, 
similar study procedures, and similar follow-up in which the 
dose and duration of primaquine treatment varied.  5,  7,  8   
   Statistical  analysis.     The data from each treatment group were 
compared by one-way analysis of variance. Non-parametric 
data were compared by the Kruskal-Wallis test. The cumulative 
cure rates were calculated by Kaplan-Meier survival analysis 
censoring for loss to follow-up or appearance of   P. falciparum  
and were compared using the log rank test. The Spearman rank 
correlation coefficient was used to evaluate the association 
between gametocyte counts, parasite counts, fever clearance, 
and parasite clearance times. All statistical analyses were 
performed using the statistical computing package SPSS 
Version 16.0 for Windows (SSPS Inc, Chicago, IL). 
    RESULTS 
  Patients .     There were 85 patients with acute vivax malaria 
14–61 years of age (mean ± SD = 24.6 ± 10.1 years). The majority 
of patients acquired malaria infection from the western border 
of Thailand (  N   = 74, 87.1%) and a high proportion (  N   = 37; 
43.5%) had had at least one malaria infection in the past year 
(median 2; range 1 to 10 attacks). All patients presented with a 
history of fever (median 4; range 1 to 20 days) before hospital 
admission. The geometric mean (range) peripheral blood 
  P. vivax   asexual parasite count was 6,205/μL (33 to 97,968/μL). 
Overall 29% ( N =  25) of patients had detectable gametocytemia 
at presentation. The median (range) gametocyte count was 
41/μL (16–110/μL). The majority of patients (88%) were 
thrombocytopenic (platelets < 180,000/μL) but none had 
significant abnormalities of other baseline hematology results 
(  Table 1  ). Between the two treatment groups randomized 
to receive 30 mg or 60 mg primaquine daily for 7 days (  N   = 43 
and 42), serum glutamic-pyruvic transferase (sGPT) concentra-
tions were significantly higher in the high dose group (median 
24; range 8 to 84 versus 19; 5 to 147 U/liter,   P   = 0.045) but 
all baseline characteristics and other laboratory findings were 
similar in the 2 groups (  P   ≥ 0.24). 
        Clinical  course.     All patients made a full clinical recovery 
after treatment. One patient developed acute tonsillitis on 
day 5 but responded well to antibiotics (amoxicillin). His 
fever cleared 201 hours after starting primaquine treatment. 
The overall mean (SD) parasite clearance time was 87.7 hours 
(25.3 hours). The overall median (range) parasite reduction 
ratios at 24 hours and 48 hours were 2 (0.1–4.1) and 14.4 
  Table  1 
    Demographic data and therapeutic responses in patients with   P. vivax   malaria in a comparison of 2 short-course primaquine-only regimens   
Treatment groups Primaquine 30 mg/day Primaquine 60 mg/day Both groups   P   values
Numbers 43 42 85
Age (years) 24.5 ± 9.9 24.6 ± 10.4 24.6 ± 10.1 0.94
Patients with previous malaria 17 20 37 0.59
No. of previous malaria infections median (range) 2 (1–10)   N   = 17 2 (1–7)   N   = 20 2 (1–10)   N   = 37 0.32
No. coming from the West of Thailand 38 36 74 0.99
History of fever (days) 4 (1–20) 4 (1–25) 4 (1–20) 0.93
Parasite count (/μL) 5,344 (33–97,968) 7,231 (445–73,476) 6,205 (33–97,968) 0.43
Hematocrit (%) 36.7 ± 5.9 35.8 ± 5.3 36.3 ± 5.6 0.50
White blood cell count (10  3 / μL) 6.9 ± 2.1 7.0 ± 2.1 7.0 ± 2.1 0.70
    Data are shown as mean ± SD or median (range) and parasite count as geometric mean  .   544 PUKRITTAYAKAMEE AND OTHERS
(0.1–1376), respectively. Between the 2 treatment groups, there 
were no significant differences in PCT or parasite reduction 
ratios (  P   ≥ 0.18). Excluding the patient with acute tonsillitis, 
the median fever clearance time was 47 hours (range 4 to 130 
hours). On admission, 55 patients (64.7%) had gastrointestinal 
symptoms i.e. nausea ( N  = 36, 42.4%), vomiting ( N =  14, 16.5%), 
abdominal pain (  N =   14, 16.5%), and diarrhea (  N =   3, 3.5%). 
These symptoms disappeared after day 3 in the majority of 
patients (  N =   48/55; 87.3%) as the malaria infection subsided 
(  Figure 1  ). Only one patient who received daily 60 mg 
primaquine had persistent but mild abdominal pain till day 
7 but this responded well to antacids. His pain resolved fully 
on the eighth day suggesting it was drug related. Transient 
localized rashes developed in 3 patients on day 0 to day 3 but 
all lasted only for 24 hours. Comparing the 2 treatment groups, 
the overall incidence of gastrointestinal symptoms during 
acute malaria (day 0–3) was significantly higher in the lower 
dose primaquine group (33/43 versus 22/44;   P   = 0.033). There 
was no other significant adverse effects or complications in the 
studied patients. 
    Laboratory  results.     The mean ± SD baseline hematocrit of 
all patients (36.3% ± 5.6%) decreased significantly after day 2 
to day 7 (  Figure 2  ,   P   < 0.001), then returned back to baseline 
values on day 14 (36.2% ± 3.7%;   P =   0.07), and became 
significantly higher than the baseline hematocrit on day 28 
(40.5% ± 3.6%,   P =   0.001). The overall median hematocrit 
reduction was 8.8% (range 2.2–33.3%). A hematocrit drop 
of > 30% was observed in 2 cases; one from each group. The 
lowest recorded value was 30% on day 6 in one case and 28% 
on day 7 for the other. Neither was associated with symptoms 
and none of the studied patients needed a blood transfusion. 
Comparing the 2 treatment groups, there were no significant 
differences in the baseline hematocrit values (36.7 ± 5.9% 
versus 35.9 ± 5.3%;   P   = 0.50), the proportion of patients with 
hematocrit reduction (  N   = 40/43 versus 37/42;   P   = 0.34) or the 
magnitude of hematocrit reductions (  Figure 2  ,   P   ≥ 0.11). 
    On admission, thrombocytopenia (platelets < 180,000/μL) 
was found in the majority of patients (87.8%;   N =   72/82).  The 
mean ± SD baseline platelet count was 111,000 ± 77,000/μL 
but then increased to above 200,000/μL in all subsequent fol-
low-up assessments (day 7, day 14, and day 28) in both groups 
( Table 2 ). Except for the reduction in hematocrit and thrombo-
cytopenia on admission, none of the studied patients showed 
significant persistent abnormal hematology findings during 
1 month monitoring. An elevation of bilirubin > 3 mg/dL was 
found on admission only in 6 patients (4 group 1, 2 group 2) and 
in 2 was accompanied by SGPT elevation (52 and 64 Units/L). 
During the follow-up assessments, serum SGPT   elevation of 
> 2-fold was found in 8 patients but all were transient and mild 
(maximum range = 84 to 199 Units/L). Except for one patient 
with a serum creatinine of 2.2 mg/dL on admission only, none 
of the studied patients had significant elevation of serum crea-
tinine (> 2.0 mg/dL) throughout the follow-up period. 
                  Plasmodium vivax   gametocytemia.     During hospital stay, 
patent gametocytemia was detected in 62.4% (  N   = 53) of 
patients, 29.4% (  N =   25) on admission and a further 32.9% 
(  N =   28) after starting primaquine treatment. The gametocyte 
carriage of all studied patients (i.e., including those without 
gametocytemia) was brief; median was 12 hours (range, 
0–74 hours) and was not significantly different between 
the two treatment groups (median 12; range 0–74 versus 7; 
  Figure   1.       Proportions of patients with gastrointestinal symptoms 
during primaquine monotherapy for   P. vivax   malaria.    
  Figure   2.       Serial hematocrits (%) levels in adult G6PD nor-
mal patients treated with primaquine of 30 mg/day (open circles) or 
60 mg/day (closed circles) for acute vivax malaria. Data are shown as 
mean  (SD).    545 SHORT COURSE PRIMAQUINE IN VIVAX MALARIA
0–60 hours;   P   = 0.49). The overall gametocyte carriage rates 
were not significantly different between the 2 groups either 
before (  N   = 15 and 10) or after treatment (  N   = 14 and 14) 
(  P   = 0.58). 
  Gametocytemia before treatment and the ratio to asex-
ual stage parasite densities were similar in the two treatment 
groups (  Table 3  ). In patients with post-treatment gameto-
cytemia, the 60 mg primaquine group showed slightly better 
suppression of gametocytemia compared with the 30 mg pri-
maquine group with lower peak gametocyte/corresponding 
asexual parasite counts ratios (0.6% versus 3%,   P   = 0.016). 
       Recurrence  rates.     Complete clinical and parasitological 
follow-up was obtained in 64 patients (75%). These patients 
were either followed-up outside the malaria transmission area 
for 28 days or remained in the hospital until the subsequent 
appearance of vivax or falciparum malaria. The remaining 25% 
of patients did not return after discharge. Their demographic 
and disease characteristics were similar to those successfully 
followed. There were no significant differences in proportion 
of loss to follow-up between the two treatment groups (12/43; 
27.9% in the 30 mg groups versus 9/42; 21.4% in the 60 mg 
groups,   P   = 0.62). 
  Of the 31 patients successfully followed in the 30 mg group, 
9 (29%) had reappearance of vivax and another one (3%) had 
emergence of falciparum malaria after a full clinical recov-
ery and parasite clearance of the primary vivax illness. The 
corresponding figures were 2/33 (6%) relapses and 3 (7%) 
  Plasmodium falciparum   recrudescences in the 60 mg group. 
The incidence of vivax reappearance was significantly lower 
in the high dose primaquine group; by Kaplan Meier survival 
analysis with day 28 relapse estimates (95% Confidence inter-
val) of 29% (16–49%) in the 30 mg group compared with 
7% (2–24%) in the 60 mg group;   P   = 0.027 (  Figure 3  ). 
    All patients with incomplete cure responded to retreatment 
with the corresponding standard regimens for vivax malaria or 
falciparum malaria. To assess these responses with primaquine 
monotherapy, we compared the results of the present study 
with the previously reported studies conducted in the same 
hospital (so reinfection could be excluded) and with similar 
patient groups with acute vivax malaria, in which primaquine 
(30 mg base or 60 mg base per day) was given together with 
artesunate (5 or 7 days) for 3, 5, or 7 days.  5,  7,  8   Artesunate  has 
no hypnozoitocidal activity but is highly effective against 
the blood stage infection. Recurrences after artesunate regi-
mens are therefore assumed to be relapses (see Supplemental 
Appendix, available at   www.ajtmh.org  ). The 60 mg/day recur-
rence rates in this study are similar to those in the previous 
studies, which suggests first that this dose gives nearly maximal 
  Table  3 
    Relationship between sexual and asexual parasitemia in patients with   P. vivax   gametocytemia  
Parameters Primaquine 30 mg Primaquine 60 mg Total   P 
Gametocyte count/μL (median; range)
Gametocytemia before treatment 36 (16–108)   N   = 15 55 (23–110)   N   = 10 41 (16–110)   N   = 25 0.06
Gametocytemia after treatment 46.5 (22–193)   N   = 14 55 (27–183)   N   = 14 49.5 (22–193)   N   = 28 0.61
All patients with gametocytemia 41 (16–193)   N   = 29 55 (23–183)   N   = 24 47 (16–193)   N   = 53 0.08
Gametocyte/parasite counts (%)
Gametocytemia before treatment 0.4 (0.9–3.4)   N   = 15 0.6 (0.1–2.6)   N   = 10 0.5 (0.1–3.4)   N   = 25 0.69
Gametocytemia after treatment 0.8 (0.1–5.4)   N   = 14 0.6 (0.1–8.3)   N   = 14 0.6 (0.1–8.3)   N   = 28 0.64
All patients with gametocytemia 0.4 (0.1–5.4)   N   = 29 0.6 (0.1– 8.3)   N   = 24 0.6 (0.1–8.3)   N   = 53 0.44
Peak gametocyte/peak parasite counts (%)
Gametocytemia before treatment 0.4 (0.1–3.4)   N   = 15 0.6 (0.1–2.6)   N   = 10 0.6 (0.1–3.4)   N   = 25 0.76
Gametocytemia after treatment 0.8 (0.1–4.0)   N   = 14 0.6 (0.2–2.4)   N   = 14 0.7 (0.1–4.0)   N   = 28 0.98
All patients with gametocytemia 0.4 (0.1–4.0)   N   = 29 0.6 (0.1–2.6)   N   = 24 0.6 (0.1–4.0)   N   = 53 0.79
Peak gametocyte/corresponding asexual parasite counts (%)
Gametocytemia before treatment 0.9 (0.1–7.7)   N   = 15 0.6 (0.1–4.0)   N   = 10 0.7 (0.1–7.7)   N   = 25 0.80
Gametocytemia after treatment 3.0 (0.2–101)   N   = 14 0.6 (0.2–8.3)   N   = 14 1.0 (0.2–101)   N   = 28 0.016
All patients with gametocytemia 1.9 (0.1–101)   N   = 29 0.6 (0.1–8.3)   N   = 24 0.9 (0.1–101)   N   = 53 0.08
  Table  2 
    Laboratory findings in patients with   P. vivax   malaria on admission and follow-up   
Parameter Primaquine 30 mg Primaquine 60 mg Both groups
Platelets (×10  9  /L) D0 111 ± 82;   N   = 41 112 ± 73;   N   = 41 111 ± 77;   N   = 82
Platelets (×10  9  /L) D7 288 ± 77;   N   = 38 274 ± 105;   N   = 37 281 ± 92;   N   = 75
Platelets (×10  9  /L) D14 281 ± 100;   N   = 34 285 ± 104;   N   = 37 283 ± 101;   N   = 71
Platelets (×10  9  /L) D28 232 ± 64;   N   = 27 227 ± 56;   N   = 32 229 ± 59;   N   = 59
Serum creatinine (mg/dL) D0 1.0 ± 0.2;   N   = 42 1.0 ± 0.3;   N   = 42 1.0 ± 0.2;   N   = 84
Serum creatinine (mg/dL) D7 0.9 ± 0.1;   N   = 39 0.9 ± 0.1;   N   = 38 0.9 ± 0.1;   N   = 77
Serum creatinine (mg/dL) D14 0.9 ± 0.1;   N   = 34 1.0 ± 0.1;   N   = 37 0.9 ± 0.1;   N   = 71
Serum creatinine (mg/dL) D28 0.9 ± 0.2;   N   = 27 0.9 ± 0.1;   N   = 32 0.9 ± 0.1;   N   = 59
Total bilirubin (mg/dL) D0 1.1 (0.4–5.4);   N   = 42 1.0 (0.1–4.1);   N   = 42 1.1 (0.1–5.4);   N   = 84
Total bilirubin (mg/dL) D7 0.6 (0.3–1.6);   N   = 39 0.6 (0.3–1.3);   N   = 38 0.6 (0.3–1.6);   N   = 77
Total bilirubin (mg/dL) D14 0.5 (0.2–1.4);   N   = 34 0.5 (0.3–1.2);   N   = 37 0.5 (0.2–1.4);   N   = 71
Total bilirubin (mg/dL) D28 0.5 (0.3–1.0);   N   = 27 0.4 (0.3–1.7);   N   = 32 0.5 (0.3–1.7);   N   = 59
SGPT (U/L) D0 24 (8–84);   N   = 42 19 (5–147);   N   = 42 21 (5–147);   N   = 84
SGPT (U/L) D7 32 (11–146);   N   = 39 24 (5–65);   N   = 38 27 (5–146);   N   = 77
SGPT (U/L) D14 35 (11–199);   N   = 34 20 (10–105);   N   = 37 26 (10–199);   N   = 71
SGPT (U/L) D28 22 (10–78);   N   = 27 18 (7–87);   N   = 32 19 (7–87);   N   = 59
    D = Days after initiation of primaquine treatment; D0 = pretreatment values.   546 PUKRITTAYAKAMEE AND OTHERS
hypnozoitocidal activity, and second that the significantly 
higher recurrence rate with the 30 mg/day primaquine mono-
therapy results predominantly from recrudescences (Supple-
mental Appendix and   Figure 4  ). 
    Factors  associated  with  gametocyte  carriage.   The  admission 
asexual parasite counts were not significantly different between 
patients with or without patent gametocytemia (  Table 4  ) 
that appeared either before or after treatment (  P   ≥ 0.11). 
Regardless of treatment groups, patients with gametocytemia 
cleared asexual parasite much slower that those without 
gametocytemia (  P   ≤ 0.018) and also had slower fever 
clearance times although this was not statistically significant 
(  P   = 0.075). This was not attributable to higher parasitemia as 
there were no significant differences in parasitemia between 
those with and without gametocytemia. There were also no 
significant differences in the numbers of previous malaria 
attacks, duration of fever, or admission hematocrit values or 
reappearance rate of vivax malaria between patients with and 
without gametocytemia (  Table 4  ). 
         DISCUSSION 
  Primaquine may be the most under-used antimalarial drug. 
Although widely recommended for the radical cure of relaps-
ing malarias (  P. vivax, P. ovale  ), it is seldom actually prescribed 
in endemic areas in the 14 day courses currently considered 
necessary for optimum effects.  10,  11   Lack of availability of test-
ing for glucose-6-phosphate dehydrogenase, concerns over the 
potential for severe hemolysis, and poor adherence to long 
courses conspire to prevent widespread use. As   P. vivax   is tra-
ditionally considered more difficult to eliminate than   P. falci-
parum  , current global initiatives against vivax malaria may be 
unsuccessful if primaquine remains only a theoretical recom-
mendation. Chloroquine resistance in   P. vivax   is now estab-
lished in several areas, notably Oceania and in Indonesia. 
As primaquine has significant asexual stage activity against 
  P. vivax  , the combination of chloroquine and primaquine 
would be expected to delay or prevent the emergence of resis-
tance. India, which harbors the majority of the world’s   P. vivax  
infections, recommended an inadequate primaquine dose reg-
imen (5 days only) for radical cure for nearly half a century, 
but perhaps the reason that chloroquine resistance did not 
emerge there was because of combination treatment against 
the asexual stage infection. If an effective radical cure could 
be given in a shorter duration than 2 weeks, then adherence 
would be expected to improve. 
  Chloroquine is still the most widely used vivax malaria 
treatment in the world. Given alone for tropical frequent 
relapse   P. vivax   infections, the first relapse which usually 
emerges at 3 weeks in Southeast Asia, is suppressed by resid-
ual therapeutic levels of chloroquine in the blood (post treat-
ment prophylaxis). Assessment of radical curative regimens 
with chloroquine therefore require long follow-up, and may 
underestimate true relapse rates. It is not known whether the 
suppressed relapse is prevented or delayed. The 8-aminoqui-
nolines are the only class of drug with radical curative activ-
ity, although there is intriguing evidence that other quinoline 
antimalarials may synergize with them in this activity.  12   Soon 
after the introduction of primaquine over 50 years ago it was 
established that radical cure was a function of the total dose 
given. Daily dosing was limited by toxicity. In this study of 
G6PD normal Thai adult males, the 7-day regimen of 60 mg 
base adult dose per day was well tolerated. It proved supe-
rior to the lower dose regimen in terms of late recurrences. As 
reinfection was excluded late recurrences could have resulted 
from either recrudescence or relapse. In previous studies in 
which primaquine was combined with artesunate, which has 
no radical curative activity but is highly effective against the 
blood stage infection,  5,  7,  8   the recurrence rate with 7 days arte-
sunate plus primaquine at a dose of 60 mg base/day was similar 
to that observed in the present study with primaquine only at 
60 mg base/day. As recurrences following artesunate regimens 
  Figure   3.       Proportions of adult patients with recurrent   P. vivax   par-
asitemia in the 30 mg/day and 60 mg/day primaquine groups.       
  Figure   4.       Recurrences following acute   Plasmodium vivax   malaria 
in adults studied in Thailand in a hospital setting for 28 days where 
reinfection was excluded. The horizontal axis shows the number of 
days for which primaquine was given. The open circles and bars rep-
resent the proportion and its 95% confidence interval of recurrences 
in patients who also received artesunate for 5 or 7 days, which has no 
hypnozoitocidal activity but is highly effective against the blood stage 
infection, together with primaquine at a daily adult dose of 30 mg 
(base).  7,  8   These recurrences are therefore assumed to be relapses. The 
grey circle shows the recurrences in adults receiving artesunate and 
primaquine 60 mg daily (7 days).  7   The black diamonds are the results 
of the present study in which primaquine was given alone. The differ-
ence between the primaquine 30 mg/day with and without artesunate 
reflects recrudescences (  A  ; arrowed) and that between primaquine 
30 mg/day with artesunate and the primaquine 60 mg/day regimens pre-
sumably reflects relapses (  B  ; arrowed). See Supplemental Appendix. 
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are likely to be all relapses this suggests that the significantly 
higher recurrence rate (29% versus 7%) with the 30 mg/day 
primaquine monotherapy resulted both from the higher rate 
of relapses (~12%) but also a greater proportion of recrudes-
cences (~17%) (Supplemental Appendix;   Figure 4  ). This indi-
cates that 30 mg/day does not provide maximum asexual stage 
activity whereas 60 mg/day provides 97% of maximal blood 
stage effect (Supplemental Appendix). The extrapolated dose-
response relationship for relapse prevention (radical cura-
tive activity) suggests that 30 mg primaquine a day for 7 days 
gives approximately 72% of maximal relapse prevention, but 
is still inferior to the 60 mg/day regimen (92% of maximum) 
(Supplemental Appendix;   Figure 4  ). These estimates are 
approximate as confidence intervals are wide, and it is possible 
that first recurrences (either relapse or recrudescence) could 
have occurred after the 28 day observation period. This con-
firms that primaquine has intrinsically weaker asexual stage 
activity than chloroquine or artemisinin derivatives,  13   and it 
suggests that the dose response relationship for radical cura-
tive activity differs to that for asexual stage activity. 
  From a practical therapeutic perspective the higher dose 
shorter course regimen, if generally well tolerated, may be a 
preferable component of combination treatment regimens 
for vivax malaria. Further studies to assess tolerability in a 
broader age range are now indicated. 
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  Table  4 
    Comparison between patients with and without patent   P. vivax   gametocytemia  
Patients with gametocytemia Patients without gametocytemia    
No. 53 32 P values
Parasite count/μL (geometric mean; range) 8031; 522–97,968 4048; 33–49,738 0.06
Previous malaria attack (numbers) 0 (0–10) 0 (0–7) 0.80
Days of fever prior to admission 4 (1–15) 3.5 (1–20) 0.74
Hematocrit % (mean ± SD) 36.5 ± 5.5 35.8 ± 5.8 0.06
Fever clearance time (hours) 53.0 (4–201) 36.5 (4–94) 0.08
PCT50 (hours) 31.9 ± 17.9 22.6 ± 15.5 0.018
PCT90 (hours) 79.1 ± 21.7 67.0 ± 18.2 0.010
Parasite clearance time (hours) 94.4 ± 23.4 76.8 ± 25.0 0.002
No. of patients with   P. vivax   reappearance/FU patients 9/37 (24.3%) 2/27 (7.4%) 0.08
    Data are shown as mean ± SD or median (range). FU = follow-up. PCT50 and PCT90 = times taken for the asexual parasite count fell by 50% and by 90% of the admission values.   